Ask AI
ProCE Banner Activity

CE / CME

Think You Know JAK? Essential Evidence to Aid Your Clinical Implementation of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo

Video

JAK inhibitors are efficacious and safe to use in several dermatologic conditions, including atopic dermatitis, alopecia areata, and vitiligo. Access this on-demand webcast to review the latest data and learn how to safely integrate FDA-approved JAK inhibitors in your practice by optimizing patient selection, risk assessment, shared decision-making, and monitoring to support patients’ individualized care and long-term disease control.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: November 17, 2026

Expiration: November 16, 2027

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners), in partnership with Decera Clinical Education and Smart Patients.

ProCE Banner

Supporters

Supported by an independent educational grant from AbbVie.

AbbVie

Partners

Decera Clinical Education

ProCE Banner

Smart Patients

ProCE Banner

Target Audience

This activity is intended for nurse practitioners and physician associates who are involved in the management of patients with alopecia areata, atopic dermatitis, and vitiligo.

Program Learning Goal

The goal of this educational activity is to improve learners’ knowledge and competence in evidence-based use of JAK inhibitor therapies for patients with alopecia areata, atopic dermatitis, and vitiligo.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate long-term safety and efficacy data for JAK inhibitors into treatment strategies for patients with atopic dermatitis

  • Evaluate recent clinical evidence for current and emerging JAK inhibitors in alopecia areata

  • Identify patients with vitiligo most likely to benefit from JAK inhibitor therapies based on emerging clinical trial evidence

  • Determine the role of JAK-STAT signaling in the pathophysiology of AA, AD, and vitiligo

  • Develop appropriate monitoring plans for patients with AA, AD, and vitiligo receiving JAK inhibitor therapy

  • Educate patients about the potential risks and benefits of JAK inhibitor therapies in AA, AD, and vitiligo

Financial Disclosures

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partner policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Erik Domingues, MD, FAAD: consultant/advisor/speaker: AbbVie, Apogee, Arcutis, Bristol Myers Squibb, Castel, Galderma, Incyte, Johnson & Johnson, Kowa, Leo, Pelthos, Pfizer, UCB, Veradermics.

Benjamin Ungar, MD: consultant/advisor/speaker: AbbVie, Arcutis, Botanix, Bristol Myers Squibb, Ebla Holdco, Galderma, Incyte, Johnson & Johnson, Leo, Lilly, Nektar, Pfizer, Sanofi, Sun, Veradermics, VRG.

Katie Smiley, PA-C: consultant/advisor/speaker: ADMA, Novartis.​

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 17, 2026, through November 16, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Generative artificial intelligence (AI) tools were used for generating clinical cases and transcript(s) from audio/video file. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Smart Patients. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.​

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Physician Associate Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credits for learning and change.